Name: GENERAL ATLANTIC, L.P. 13F Holdings
Creator: 13F Insight

AI Analysis · Q2 2026

General Atlantic's $2.15 billion U.S.-listed public portfolio for March 2026 reflects a growth-equity manager in the middle of a deliberate sector rotation within its healthcare exposure while maintaining overwhelming conviction in its core fintech complex. The quarter's defining event at the portfolio level was a $260 million liquidation of Alignment Healthcare, a Medicare-advantage insurance platform that the firm had carried through multiple prior quarters. That exit was entirely contained within the portfolio's healthcare sleeve: at the same time, the firm liquidated three other late-stage biopharma positions, cutting Revolution Medicines by 74.8% (−$155M), Centessa Pharmaceuticals by 77.9% (−$99M), and Nurix Therapeutics by 16.2% (−$29M). The combined healthcare drawdown of approximately $544 million is best understood not as a withdrawal from the sector but as a rotation away from late-stage, clinical-readout-driven names toward an earlier-stage, genetically-targeted rare-disease play that the firm has chosen to hold — Pharvaris, held flat at $227 million. The freed capital was not explicitly redeployed into new names; instead, it appeared to absorb some of the broader AUM decline that the fund experienced across Q1, as reported values fell in the broader venture-backed portfolio alongside market revaluations of growth stocks. Yet within the portfolio that remained, the firm's conviction in its emerging-market payments and neobanking complex was undiminished — dLocal was held flat at 46.7 million shares and $605 million, the portfolio's largest position despite a 8.2% price-driven decline. XP Inc, the Brazilian digital banking and financial-services platform, was trimmed slightly by 9.4% (from 22.7 to 20.6 million shares) but retained as the portfolio's second- or third- largest holding at $392 million. Chime, the U.S. neobank in which General Atlantic has been a long-term holder, was increased meaningfully — adding 3.4 million shares at $98 million — suggesting continued confidence in U.S. consumer neobank economics at a time when the sector faced net-interest-margin headwinds. The Alkami Technology position, a U.S. digital-banking platform focused on credit unions and community banks, was the portfolio's most tactically decisive increase, growing share count by 27.9% at $363,000-share increment. All three positions — dLocal, XP, and Chime — share a common thesis: that digital banking and payments infrastructure in developing and mid-market banking systems will consolidate around a small number of platform companies that benefit from network effects and switching costs. The Alkami addition is a clear signal that General Atlantic is doubling down on that same thesis in a North American context. For readers tracking growth-equity positioning, the headline is that General Atlantic is running a focused fintech story at a time when the broader venture and growth universe has been under valuation pressure, and that it has been willing to absorb the markdowns in its later-stage healthcare positions without reducing its commitment to the core.

The Alignment Healthcare exit is the most visible healthcare trade. Alignment is a Medicare Advantage and Medicare Prescription Drug plan operator that had been carried in the portfolio at $260 million on 13.2 million shares in the prior quarter; the position was liquidated completely in Q1. Alignment's business model is dependent on the risk-adjusted revenue payments it receives from CMS for managing Medicare enrollees, and the Medicare Advantage market has faced pricing headwinds in recent years as CMS reimbursement rates have failed to keep pace with medical-cost inflation. A growth-equity manager who built Alignment at a meaningful size and then exits entirely is either concluding that the thesis has run its course or that a better risk-adjusted deployment is available elsewhere. Either outcome — exits at a loss or exits at a thesis-reassessment — is consistent with the filing. The simultaneity of the Alignment exit alongside the three additional late-stage biopharma reductions (Revolution Medicines, Centessa, Nurix Therapeutics) indicates a deliberate portfolio-construction decision to reduce exposure to clinical-stage, binary-event biopharma names rather than a reaction to a single stock disappointment.

Revolution Medicines at $69 million, down from $224 million, and Centessa Pharmaceuticals at $54 million, down from $153 million, are the largest dollar reductions in the healthcare sleeve and the most instructive. Both companies had been held in a form characteristic of late-stage biopharma venture portfolios: pre-revenue or minimally-revenue companies whose value depends on the success or failure of late-stage clinical trials in a specific therapeutic area. Revolution Medicines is a targeted-therapy company working on therapies in oncology, and Centessa is a clinical-stage biopharmaceutical company targeting complement-system diseases. The combination of the timing — both positions reduced substantially in a single quarter — and the firm's simultaneous retention of Pharvaris at $227 million suggests that the manager has made a deliberate bet within the rare-disease-and-oncology complex to concentrate risk in one name rather than distribute it across three. Pharvaris, a biopharmaceutical company focused on hereditary angioedema and other rare complement-system diseases, has a clinical program that is more advanced than either Revolution or Centessa at the portfolio-manager's assessment, and the firm's decision to hold that position while liquidating the others is consistent with a bottom-up comparison of risk-adjusted upside within the therapeutic area.

Quarter at a glance — Q2 2026

Top 10 holdings

Filing history